Compare Organon & Co. Common Stock (OGN) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Symbotic Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Symbotic Inc trades at $37.5 (market cap $5.31B). The key difference: Symbotic Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Symbotic Inc for 24 Days on average.
| OGN | SYM | |
|---|---|---|
Market Cap | $3.62B | $5.31B |
Volume | 2,892,999 | 1,244,339 |
Sector | Health | Industrials |
52-Week High | $13.81 | $87.30 |
52-Week Low | $5.70 | $37.90 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $11.04B | $3.56B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SYM trades at $40.89, down 32% year-to-date and near 52-week lows, with bearish technical signals dominating. Fundamentally, the company shows mixed results with a $22.5 billion backlog and 20%+ revenue growth but negative EBITDA of -$48M and net loss of -$17M in 2025. Recent earnings misses and high customer concentration (85% revenue from Walmart) create uncertainty despite analyst optimism.
The stock presents a high-risk opportunity with significant upside potential if execution improves. Analyst consensus targets $60.33 (47% upside) but near-term risks include continued earnings misses, customer concentration, and weak technical momentum. The 2027 inflection point for new system deployments represents the key growth catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
